CLCS (Cell Source) Pre-Tax Income: $-4.51 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLCS Cell Source Inc CLCS
35 GF Score
Price $0.64
View Full Analysis

What is Cell Source Pre-Tax Income?

Cell Source CLCS -25.58% 35 Pre-Tax Income is $-4.51 Mil as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Pretax income is the income that a company earns before paying income taxes. Cell Source's pretax income for the three months ended in Dec. 2024 was $-0.33 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.51 Mil. Cell Source's pretax margin was %.

Cell Source  (OTCPK:CLCS) Pre-Tax Income Explanation

Cell Source's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.331/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Pre-Tax Income Related Terms

Cell Source Pre-Tax Income Historical Data

* Premium members only.

The historical data trend for Cell Source's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Pre-Tax Income Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.56 -5.47 -5.17 -5.32 -4.51

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -1.28 -1.49 -1.42 -0.33

CLCS vs EDSA, CTXR, ASBP: Pre-Tax Income Comparison

For the Biotechnology subindustry, Cell Source's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source Pre-Tax Income vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cell Source's Pre-Tax Income falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Pre-Tax Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cell Source's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-3.84+0.416+-1.088+0+-0.0010000000000003
=-4.51

Cell Source's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.677+0.48+-0.134+0+5.5511151231258E-17
=-0.33

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pre-Tax Income →
What does a Pre-Tax Income of $-4.51 Mil mean?
Cell Source (CLCS) has a Pre-Tax Income of $-4.51 Mil as of Dec. 2024. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Cell Source and its competitors.
Is Cell Source's Pre-Tax Income too high?
Cell Source's current Pre-Tax Income is $-4.51 Mil. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Pre-Tax Income compare to EDSA and CTXR?
Cell Source's Pre-Tax Income of $-4.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Cell Source and its competitors. Cell Source's current Pre-Tax Income is $-4.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Pre-Tax Income of $-4.51 Mil. The current Pre-Tax Income is $-4.51 Mil. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Cell Source (CLCS), the current Pre-Tax Income is $-4.51 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price